TGFB1 and breast carcinoma: Therefore, our results of mRNA sequencing, immunofluorescence imaging, and immunoblotting suggested that 3oc activated the TGF-β and ErbB2 pathways in breast cancer cells, which rendered breast cancer cells insensitive to trastuzumab.